PUMA Aktie 481322 / DE0006969603
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
|
11.11.2025 16:00:03
|
EQS-News: PUMA shifts to licensing model with United Legwear Company LLC in the US and Canada
|
EQS-News: PUMA SE
/ Key word(s): Miscellaneous
PRESS RELEASE
PUMA shifts to licensing model with United Legwear Company LLC in the US and Canada Herzogenaurach, November 11, 2025 – Sports company PUMA will move from a business partnership to a licensing agreement structure with its long-term partner United Legwear Company LLC (ULAC) that allows the company to sell PUMA branded products, mainly socks and underwear, but also including children’s apparel and accessories in the United States and Canada. This change took effect on November 1, 2025. Previously, PUMA and United Legwear Company LLC had a partnership, PUMA United, which focused on the sale of these products in the U.S. and Canada. PUMA held a 51% capital share in PUMA United. The products sold by PUMA United were manufactured, transported, and stored by United Legwear and its suppliers. The move from a partnership to an exclusive licensing agreement is part of PUMA’s strategic initiative to reduce complexity within its operating model in North America and sharpen the focus on its core business in the region. It further solidifies the continued close partnership between PUMA and ULAC which has existed for 25 years. As outlined during its third-quarter results on October 30, PUMA is executing a reset and is optimizing its distribution network. At that stage, PUMA had already said it was considering a shift to a licensing model with United Legwear. Financial details of the new licensing agreement with United Legwear are not disclosed. This transition to a licensing model aligns with market practices in North America, where the production and sale of such products are typically licensed to third parties. Through this shift, PUMA aims to create a leaner, more efficient business model while maintaining a strong brand presence in these categories via its valued long-term licensing partner. The transition also enhances transparency for investors and the capital market by enabling clearer financial reporting. As a result of this change, PUMA United will be classified as a discontinued operation in PUMA’s financial reporting from November of 2025 onwards. Accordingly, current year and prior-period figures will be restated, with PUMA United’s results, assets, and liabilities presented separately from continuing operations. Sales generated by the partnership amounted to €427.9 million, while net earnings attributable to non-controlling interests were €60.7 million for the 2024 financial year. For additional information regarding disclosures on non-controlling interests, please refer to page 315 of the PUMA Annual Report 2024. Media Contact: Robert-Jan Bartunek – PUMA Corporate Communications – robert.bartunek@puma.com PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For more than 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.
11.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | PUMA SE |
| PUMA WAY 1 | |
| 91074 Herzogenaurach | |
| Germany | |
| Phone: | +49 9132 81 0 |
| Fax: | +49 9132 81 42375 |
| E-mail: | investor-relations@puma.com |
| Internet: | www.puma.com |
| ISIN: | DE0006969603 |
| WKN: | 696960 |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2227872 |
| End of News | EQS News Service |
|
|
2227872 11.11.2025 CET/CEST
Nachrichten zu PUMA SE
|
17:58 |
Gute Stimmung in Frankfurt: Börsianer lassen MDAX schlussendlich steigen (finanzen.ch) | |
|
16:00 |
EQS-News: PUMA shifts to licensing model with United Legwear Company LLC in the US and Canada (EQS Group) | |
|
16:00 |
EQS-News: PUMA wechselt mit United Legwear Company LLC zu einem Lizenzmodell in den USA und Kanada (EQS Group) | |
|
15:58 |
MDAX aktuell: MDAX nachmittags auf grünem Terrain (finanzen.ch) | |
|
09:28 |
Börse Frankfurt in Rot: MDAX zum Handelsstart mit Abgaben (finanzen.ch) | |
|
10.11.25 |
Montagshandel in Frankfurt: MDAX steigt am Nachmittag (finanzen.ch) | |
|
10.11.25 |
MDAX-Handel aktuell: So bewegt sich der MDAX aktuell (finanzen.ch) | |
|
07.11.25 |
EQS-PVR: PUMA SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group) |
Analysen zu PUMA SE
| 07:16 | PUMA Sector Perform | RBC Capital Markets | |
| 05.11.25 | PUMA Halten | DZ BANK | |
| 03.11.25 | PUMA Neutral | UBS AG | |
| 31.10.25 | PUMA Buy | Goldman Sachs Group Inc. | |
| 31.10.25 | PUMA Hold | Deutsche Bank AG |
Mittwoch um 18 Uhr live: Die Illusion der Erinnerung - Wie du Denkfehler im Trading vermeidest
Erfahrung ist wertvoll - doch Erinnerungen sind trügerisch. Sie verzerren, ergänzen oder lassen Details weg, bis ein falsches Bild entsteht. Dieses Webinar zeigt, warum das Gehirn keine objektive Aufzeichnung liefert und wie diese Verzerrungen Trading-Entscheidungen unbewusst beeinflussen.
Schnell noch Plätze sichern!Abnehmspritzen – Ist der Hype vorbei? – mit Tim Schäfer
Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen? 💉📉
Im heutigen Gespräch mit Tim Schäfer @TimSchaeferMedia sprechen wir über die spannendsten Pharmawerte 2025. Neben den Abnehmspritzen blicken wir auch auf klassische Pharma-Giganten wie Pfizer, Johnson & Johnson, Roche, Novartis, AstraZeneca und GSK. Tim analysiert Übertreibungen, Rücksetzer und langfristige Chancen für Buy-and-Hold-Strategien – mit Fokus auf Dividende, KGV und Krisenresistenz.
💬 Was ist vom Abnehmtrend langfristig zu halten?
💬 Welche Pharma-Aktien sind aktuell unterbewertet?
💬 Was spricht für konservative Dividendenwerte im Gesundheitssektor?
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Warten auf anstehende Datenflut: Dow schlussendlich stark -- SMI letztlich fester -- DAX schliesslich freundlich -- Märkte in Fernost enden uneinheitlichSowohl der heimische als auch der deutsche Aktienmarkt präsentierten sich am Dienstag fester. Der US-Aktienmarkt bewegte sich am Dienstag in unterschiedliche Richtungen. Die wichtigsten asiatischen Börsen zeigten sich am Dienstag uneins.


